Islet autoantibody status in a multi-ethnic UK clinic cohort of children presenting with diabetes

R Perchard, 1,2, D MacDonald, 3 J Say, 1 J Pitts, 2 S Pye, 3 J Allgrove, 1 K Banerjee, 2 R Amin 4

ABSTRACT

Objective We prospectively determined islet autoantibody status in children presenting with diabetes to a single UK region in relation to ethnicity.

Design 316 (68.0% non-white) children presenting with diabetes between 2006 and 2013 were tested centrally for islet cell autoantibodies (ICA) and glutamic acid decarboxylase autoantibodies (GAD-65) at diagnosis, and if negative for both, tested for insulin autoantibodies (IAA). The assay used to measure GAD-65 autoantibodies changed from an in-house to a standardised ELISA method during the study.

Results Even with use of the standardised ELISA method, 25.8% of children assigned a diagnosis of type 1 diabetes still tested negative for all three autoantibodies. 30% of children assigned a diagnosis of type 2 diabetes were autoantibody positive, and these had the highest glycated haemoglobin (HbA1c) levels at 12 months follow-up compared with other groups (p value for analysis of variance <0.001), although the sample size was small. Autoantibody positivity was similar between non-white and white children regardless of assay used (60.0% (n=129) vs 56.4% (n=57), χ2=0.9, p=0.35), as was mean GAD-65 autoantibody levels, but fewer non-white children had two or more autoantibodies detectable (13% (n=28) vs 27.7% (n=28), χ2=12.1, p=0.001).

Conclusions Islet autoantibody positivity was associated with a more severe phenotype, as demonstrated by poorer glycaemic control, regardless of assigned diabetes subtype. Positivity did not differ by ethnic group.

INTRODUCTION

The UK National Diabetes Audit shows that 9% of adults have type 1A diabetes (T1D), with most of the remainder registered as having type 2 diabetes (T2D). For T1D compared with T2D adult populations, risk of vascular complications, intermediate outcomes and years of life lost are greater and treatment targets are less likely to be achieved. 2 Given these adult outcomes, the possible effect of obesity on presentation with diabetes, 3 and future prospects for interventions to preserve beta-cell function, 4 it is increasingly important for paediatric diabetes practitioners to clearly define diabetes subtype for a child presenting with diabetes and align relevant care processes and treatments accordingly.

Islet autoantibodies are important markers of T1D-associated autoimmunity. 5 However, the UK Prospective Diabetes Study (UKPDS) showed that 12% of adults with T2D in this trial tested positive for islet autoantibodies, and this was associated with increased future risk of requiring insulin. 6 In a clinic setting, the latest UK National Paediatric Diabetes Audit shows that 96.4% and 1.3% of children and young persons have been assigned a diagnosis of T1D and T2D, respectively. 1 Yet, with more detailed investigation, the landmark US SEARCH study showed that 54.5% of young people had an autoimmune plus insulin-sensitive (IS) phenotype consistent with T1D, and 15.9% had a non-autoimmune insulin-resistant (IR) phenotype, consistent with T2D, 7 with the remainder having a mixed phenotype. In addition, there was evidence of ethnic differences in islet positivity during SEARCH: fewer non-white children (mostly Hispanic and Afro-American) had an autoimmune IS phenotype, and more had a non-autoimmune IR phenotype. 8 In a separate US study, Libman et al found that black children were less likely to have autoantibodies.

We determined islet autoantibody status in a clinic setting in children and young persons from a majority non-white (largely black African and South Asian) region of inner London who presented with diabetes between 2006 and 2013.

METHODS

Patient selection

Our cohort consisted of children from two paediatric diabetes centres (Queens Hospital in Romford
and The Royal London Hospital) diagnosed with diabetes between January 2006 and April 2013 by specialist paediatric diabetes practitioners and aged <19 years. A diagnosis of T1D was assigned according to American Diabetes Association and International Society for Paediatric and Adolescent Diabetes guidelines after careful consideration by a paediatric diabetologist of the clinical presentation, biochemical abnormalities, the need for insulin and the total daily insulin dose, and the presence of islet autoantibodies. The diagnosis was reconsidered in light of symptoms and signs of a rarer form of diabetes (in which case genetic mutation analysis for monogenic diabetes was requested). If a child had negative islet autoantibody status, then a diagnosis of T1D was unaltered in the absence of other symptoms and signs—for example, insulin resistance or syndromic features. Diagnosis of T2D was considered in the presence of obesity, a family history of T2D and evidence of insulin resistance clinically (acanthosis nigricans), biochemically (normal or raised insulin and C-peptide levels during fasting or an oral glucose tolerance test and outside of the honeymoon period) and therapeutically (daily insulin requirements >1.5 units/kg and significant response to oral hypoglycaemic agents).

Islet autoantibody status only became known at the following, usually the first, clinic appointment. Clinical and demographic data were prospectively collected during clinic visits and entered on to a dedicated diabetes database. Ethnicity was self-reported and coded according to the UK Office of National Statistics 2010 census guidelines. For this study, children and young persons were grouped into three categories: white, South Asian and black (migrants to the UK of black African descent). Ethics committee approval was not sought because no interventions were performed for the purpose of the study.

**Assays**

Blood samples for measurement of autoantibodies were collected by venepuncture at initial presentation, allowed to clot, and the serum separated as soon as possible to prevent haemolysis. Serum was stored at 2–8°C. Blood samples were processed centrally at the immunology department at the Royal London Hospital and recorded electronically. The department operated a test selection policy whereby initially only islet cell antibodies (ICA) and glutamic acid decarboxylase (GAD-65) autoantibodies are measured, and, if these were negative, then insulin autoantibodies (IAA) were measured. A patient was considered autoantibody positive if at least one autoantibody was positive.

Before July 2007, samples were sent to the Protein Reference Unit at Sheffield for IAAs testing, using fluorescence enzyme immunoassay on the Phadia250 (Thermo Scientific). It uses their ImmunoCAP Specific IgG methodology and is designed as a sandwich immunoassay. The insulin antigen, covalently coupled to the solid phase, reacts with any specific IgG antibodies present in the patient sample. After washing away of non-specific IgG antibodies, enzyme-labelled antibodies against IgG are added to form a complex. After incubation and a wash step, the bound complex is then incubated with a developing agent. After the reaction is stopped, the fluorescence of the eluate is measured. The higher the fluorescence, the more specific IgG antibodies are present in the sample. A cut-off of 5 mg/L was established following an internal evaluation and audit by the Protein Reference Unit.

**Statistical analysis**

Information on islet autoantibody status on the diabetes database was validated against results from the centralised immunology department electronic database at the Royal London Hospital. Given potential concerns that the assay method for measuring GAD-65 autoantibodies varied over three different time periods, for individuals assigned a diagnosis of T1D, we included data from any time point if they tested autoantibody positive. Those with T1D who tested autoantibody negative in the time periods up to January 2012 were excluded from analysis because of the limitations of the assays used to measure GAD-65 autoantibodies before this time—that is, for the analysis, T1D autoantibody-negative individuals were only from the time period after January 2012 as this is when the standardised GAD-65 autoantibody assay was used. Data on clinical and biochemical variables were summarised as means and compared between the four independent groups using a Student t test or analysis of variance (ANOVA) model and by the χ² test. For ANOVA testing, all variables were normally distributed, and we tested differences in variance between the four groups. SPSS V16.1 was used for all analysis. A p value <0.05 was taken as significant.

**RESULTS**

Between January 2006 and April 2013, 316 children with diabetes had two or more islet autoantibody levels measured at...
diagnosis. Of these, 296 (93.7%) were assigned a diagnosis of T1D, and the remainder were assigned a diagnosis of T2D. The latter group were all prescribed metformin therapy, and five were on once daily insulin glargine.

**Islet autoantibody status**

From 316 children presenting with diabetes during the study period, 192 (60.8%) tested positive for any islet autoantibody using any assay. Median time from diagnosis of diabetes to islet autoantibody testing was 0.1 years (range 0–0.7). During the three time periods when the GAD-65 autoantibody assay changed from an in-house ELISA method (before July 2007) to an indirect immunofluorescence method (August 2007 to December 2011) and then a standardised RSR ELISA method (from January 2012), the frequency of GAD-65 positivity increased significantly and hence the frequency of children testing positive for any autoantibody increased (table 1). Mean GAD antibody levels for those who tested positive were 477.9 units/mL (SD 714.6).

We then compared the phenotype according to the assigned diabetes subtype and islet autoantibody status by dividing the cohort into four groups; T2D±autoantibody positivity and T1D±autoantibody positivity (the T1D autoantibody-negative group was restricted to those who tested negative after January 2012 as discussed in the methods, n=68).

Even with use of the standardised ELISA method for measurement of GAD-65 autoantibody, 25.8% of children assigned a diagnosis of T1D still tested negative for all three autoantibodies (table 1), but no differences in phenotype were observed when compared with autoantibody-positive T1D children (table 2).

Children assigned a diagnosis of T2D were older at presentation and heavier than those with T1D. Some 30% were autoantibody positive, and these had higher HbA1c at follow-up and body mass index (BMI) SD scores (SDSs) than the remainder of the cohort (table 2 and figure 1). Owing to the small sample, we were unable to evaluate any differences in insulin requirements.

There was no association with age and number of islet autoantibodies measured and the number of islet autoantibodies that tested positive. In addition, there was no association with age and islet autoantibodies positivity by ethnicity.

**Ethnicity**

Non-white children had a greater BMI SDS than white children (0.8 (1.9) vs 0.4 (1.4), p<0.001). In non-white (215 from 316, 68.0%) versus white children, ICA positivity was 38.1% vs 25.5% (χ²=3.4, p=0.06) and IAA positivity was 24.0% vs 25.3% (χ²=1.1, p=0.66). GAD-65 positivity was 13.2% vs 36.4% (χ²=3.1, p<0.001) before July 2007 using the in-house ELISA method, 14.4% vs 12.1% (χ²=0.9, p=0.49) between August 2007 and December 2011 using indirect immunofluorescence, and 67% vs 65% (χ²=0.7, p=0.84) after January 2012 using the standardised ELISA method. Mean GAD-65 antibody levels for those who tested positive for GAD-65 did not differ by ethnicity (non-white vs white; 345.1 (690.3) vs 309.5 (602.1) units/mL, p=0.84). Overall autoantibody positivity during the study period was similar between non-white and white children (60.0% (n=129) vs 56.4% (n=57), χ²=0.9, p=0.35), but fewer non-white children had two or more autoantibodies detectable (13% (n=28) vs 27.7% (n=28), χ²=12.1, p=0.001). HbA1c levels did not differ by autoantibody status in

---

**Table 1** Islet autoantibody status during changes in GAD-65 autoantibody assay methods

<table>
<thead>
<tr>
<th>Sample size (T1D/T2D)</th>
<th>Before July 2007</th>
<th>August 2007–December 2011</th>
<th>After January 2012</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size (T1D/T2D)</td>
<td>81 (77/4)</td>
<td>167 (157/10)</td>
<td>68 (62/6)</td>
<td>0.61</td>
</tr>
<tr>
<td>GAD-65 assay</td>
<td>In house ELISA</td>
<td>Indirect immunofluorescence</td>
<td>Standardised ELISA</td>
<td></td>
</tr>
<tr>
<td>GAD-65 +ve (%)</td>
<td>18.4</td>
<td>13.3</td>
<td>66.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ICA +ve (%)</td>
<td>50.6</td>
<td>38.2</td>
<td>45.0</td>
<td>0.18</td>
</tr>
<tr>
<td>IAA +ve (%)</td>
<td>26.5</td>
<td>24.0</td>
<td>21.9</td>
<td>0.88</td>
</tr>
<tr>
<td>Positivity for any antibody (%)</td>
<td>64.6</td>
<td>49.1</td>
<td>72.2</td>
<td>0.002</td>
</tr>
<tr>
<td>T2D with antibody positivity (%)</td>
<td>50.0</td>
<td>10.0</td>
<td>50.0</td>
<td>0.2</td>
</tr>
<tr>
<td>T1D with antibody negativity (%)</td>
<td>32.4</td>
<td>44.2</td>
<td>25.8</td>
<td>0.09</td>
</tr>
</tbody>
</table>

IAA, insulin autoantibody; ICA, islet cell autoantibody; GAD, glutamic acid decarboxylase; T1D, type 1A diabetes; T2D, type 2 diabetes.

**Table 2** Phenotype in relation to diabetes subtype and islet autoantibody status

<table>
<thead>
<tr>
<th>T2D antibody +ve (n=6) (19.5%)</th>
<th>T1D antibody –ve (n=16) (25.8%)</th>
<th>T1D antibody +ve (n=186) (59.1%)</th>
<th>T2D antibody –ve (n=14) (4.4%)</th>
<th>p Value for ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-white, n (%)</td>
<td>4 (66.7)</td>
<td>12 (75.0)</td>
<td>139 (74.7)</td>
<td>11 (79)</td>
</tr>
<tr>
<td>Age at diagnosis of diabetes (years)</td>
<td>12.5 (3.7)</td>
<td>10.6 (4.6)</td>
<td>9.1 (4.3)</td>
<td>9.3 (4.3)</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
<td>2.1 (2.6)</td>
<td>0.6 (0.3)</td>
<td>1.9 (2.3)</td>
<td>1.9 (2.3)</td>
</tr>
<tr>
<td>HbA1c at diagnosis, % (SD/mmol/l)</td>
<td>10.6 (2.3)</td>
<td>9.7 (3.6)</td>
<td>9.6 (2.2)</td>
<td>9.5 (2.2)</td>
</tr>
<tr>
<td>HbA1c 12 months after diagnosis, % (SD/mmol/l)</td>
<td>92</td>
<td>83</td>
<td>81</td>
<td>80 (2.4)</td>
</tr>
<tr>
<td>BMI SDS at presentation</td>
<td>2.0 (2.2)</td>
<td>0.6 (1.4)</td>
<td>0.7 (1.6)</td>
<td>0.7 (1.6)</td>
</tr>
<tr>
<td>On insulin treatment, n (%)</td>
<td>1 (16.7)</td>
<td>16 (100)</td>
<td>186 (100)</td>
<td>186 (100)</td>
</tr>
</tbody>
</table>

The T1D autoantibody-negative group was restricted to those who tested negative after January 2012, as this is when the standardised RSR ELISA method for GAD-65 autoantibody measurement was used—that is, T1D-negative children diagnosed before January 2012 were excluded.

Unless otherwise noted, values are mean (SD).

BMI, body mass index; HbA1c, glycated haemoglobin; SDS, standard deviation score; T1D, type 1A diabetes; T2D, type 2 diabetes.

---

the three ethnic groups. There were more girls in the non-white group (n=121 (62%)) vs n=48 (40%), p<0.001), but no gender differences were found in autoantibody status. No differences were observed within ethnic groups (black African and South Asian).

**DISCUSSION**

In this multi-ethnic UK clinic cohort of childhood-onset diabetes, we aimed to determine the percentage of children assigned a diagnosis of T1D or T2D who tested positive for at least one autoantibody. Despite use of a standardised ELISA method for GAD-65 autoantibody, 25.8% of children assigned a diagnosis of T1D still tested negative for all three autoantibodies, but no phenotypic difference existed in these compared with autoantibody-positive T1D children. Some 30% of children assigned a diagnosis of T2D were autoantibody positive, and these had the highest HbA1c at the 12-month follow-up (p value for ANOVA <0.001) and BMI (p value for ANOVA <0.001). We found no overall difference in rates of autoantibody positivity between ethnic groups at presentation with diabetes.

Studies that have added to our knowledge of the phenotype of children presenting with diabetes include the landmark US SEARCH6 and TODAY Studies,15 a study in German and Austrian children presenting with diabetes include the landmark US SEARCH,6 and TODAY Studies,15 a study in German and Austrian children presenting with diabetes. Between studies, T2D, type 2 diabetes.

**Figure 1** Glycated haemoglobin (HbA1c) levels (±SE) at diagnosis in relation to diabetes subtype and islet autoantibody status. The T1D autoantibody-negative group was restricted to those who tested negative after January 2012, as this is when the standardised RSR ELISA method for GAD-65 autoantibody measurement was used—that is, T1D-negative children diagnosed before January 2012 were excluded. Ab, antibody; ANOVA, analysis of variance; T1D, type 1A diabetes; T2D, type 2 diabetes.

**Limitations of the study**

Our sample size was small, and we did not have C-peptide measurements, HLA genotyping, measurements of insulin sensitivity or deep clinical phenotype to support some of our observations. It is likely that diagnostic accuracy may have changed over time; however, the same diagnostic criteria were applied to each patient throughout the study by the same physicians.

**Limitations of the assays**

The sensitivity and specificity for ICA indirect immunofluorescence are 85% and 98%, and for GAD ELISA testing are 92% (n=50) and 98% (n=100), respectively. The GAD ELISA has a cut-off of ≤5 U/mL and a lower detection rate at +2SDs of 0.57 U/mL. The interassay precision of the kit has been shown to have a coefficient of variation of 5.7% with a sample of 96.9 U/mL and 5.2% for a sample of 21.0 U/mL (n=20). The intra-assay precision was 7.3% for a sample of 97.2 U/mL and 8.5% for a sample of 20.0 U/mL (n=25). Indirect immunofluorescence was the method used to test GAD-65 autoantibodies between August 2007 and December 2011. This method relies on a subjective assessment of the slides under a microscope, and is therefore subject to operator error. However, the results were always
checked by a second operator, and, if there were any equivocal results, then the test was repeated. The laboratory also carried out monthly screening audits whereby known antibody-positive or negative samples, including ICA and GAD autoantibodies, were tested and read by all screeners to ensure consistency in interpretation, and results were analysed, fed back and discussed. Another consideration is that the filters and optics of the microscope will influence the sensitivity of the kit, but this was minimised by regular testing and maintenance of the microscope. A recognised limitation of ICA testing with immunofluorescence is the potential for another autoantibody, such as anti-nuclear antibody or anti-mitochondrial antibody, to hide or be confused with GAD-65. This could potentially also be relevant for GAD-65 autoantibody testing with immunofluorescence. These factors may have influenced our lower sensitivity for GAD-65 autoantibodies using indirect immunofluorescence compared with ELISA. All test methods would be run with internal quality controls and the testing laboratory would be Clinical Pathology Accredited accredited and participate in national external quality assurance (NEQAS), which highlights any issues with the laboratory processes or test protocols/methods. However, these controls and NEQAS samples would, in the majority of cases at least, be using adult sera and may not always be relevant in the paediatric population.

Conclusions

This is the first UK study to date that evaluates islet autoantibody status and phenotype in relation to specific ethnic groups in a cohort of both T1D and T2D children using information routinely collected during clinic appointments. The effect of islet autoantibody status on disease progression is unclear in those assigned a diagnosis of T2D and requires further study. Overall islet autoantibody positivity did not differ by ethnicity.

Contributors All authors listed meet the ICMEI recommendations for authorship. All authors listed made a substantial contribution to the design of the work or the acquisition, analysis or interpretation of data for the work. RP, DMacD and RA drafted the work, and all authors revised it critically for important intellectual content.

Competing interests None.

Ethics approval Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and licence their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ Powerful tests and islet autoantibody positivity in children with T1D.

REFERENCES


13. Glutamic Acid Decarboxylase (GAD) Autoantibody ELISA kit form RSR-Instructions for use (kit insert).


Islet autoantibody status in a multi-ethnic UK clinic cohort of children presenting with diabetes

R Perchard, D MacDonald, J Say, J Pitts, S Pye, J Allgrove, K Banerjee and R Amin

Arch Dis Child 2015 100: 348-352 originally published online November 19, 2014
doi: 10.1136/archdischild-2014-306542

Updated information and services can be found at:
http://adc.bmj.com/content/100/4/348

These include:

References
This article cites 21 articles, 7 of which you can access for free at:
http://adc.bmj.com/content/100/4/348#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (204)
Diabetes (339)
Immunology (including allergy) (2018)
Child health (3922)
Metabolic disorders (761)
Drugs: CNS (not psychiatric) (497)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/